Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures

NCT03336242 is registered in ClinicalTrials.gov with Radius Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03336242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03336242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures
Lead sponsor
Radius Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 29, 2017
Completion date
May 29, 2019
Enrollment
20 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

childhood absence epilepsy